Global Ophthalmic Drugs Market Forecast up to 2024
- October, 2018
- Domain: Healthcare - Pharmaceuticals
Pages:
104
Tables:
19
Charts:
57
Regions/Countries:
4 / 0
Companies:
12
Enquiry Hours:
10
- Get Free 10% Customization in this Report
[104 Report Pages] This market research report identifies Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akorn Inc., and Johnson & Johnson as the major vendors operating in the global Ophthalmic Drugs market. This report also provides a detailed analysis of the market by indication type (Dry Eyes, Glaucoma, Eye Infection/Inflammation, Retinal Disorders, and others) and region (North America, Europe, Asia Pacific, and Rest of the World).
Overview of the Ophthalmic Drugs Market
Infoholic’s market research report predicts that the global Ophthalmic Drugs market is expected to grow at a CAGR of 6.3% during the forecast period 2018–2024. Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. The American Academy of Ophthalmology has stated that nearly 11 million individuals in the US are currently suffering from age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations in eye ailments worldwide contribute to the development of the Ophthalmic Drugs market.
The other significant aspects that help in the improvement the market is high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, the hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.
According to the ophthalmic drugs industry analysis, North America accounted for the largest share of the market in 2017. It was followed by Europe, Asia Pacific, and Rest of the World. North America alone occupied more than 35% of the ophthalmic drugs market, with a significant contribution from the US to market growth.
Ophthalmic Drugs Market Competitive Analysis and Key Vendors
In future, several blockbuster drugs that have dominated the market, are expected to lose their patents. The patents of successful products accounted for over $6 billion. The loss of patent is the most important aspect imposing a major threat to the leaders in the Ophthalmic Drugs market., Lupin Pharmaceuticals received US FDA approval in February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceutical. Meanwhile, Allergan is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate a strong burden on the market players.
Some of the key vendors in the Ophthalmic Drugs market are:
- Novartis AG
- Pfizer
- Allergan Inc.
- Valeant Pharmaceutical International
- Santen Pharmaceutical Co. Ltd.
- Regeneron Pharmaceutical
- Johnson and Johnson
Ophthalmic Drugs Market by Indication
- Dry Eyes
- Glaucoma
- Eye Infection/Inflammation
- Retinal Disorder
- Others
In 2017, the market was dominated by Retinal Disorder segment and expected to be the fastest growing segment. However, Glaucoma was the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.
Ophthalmic Drugs Market Research Benefits
The report provides detailed information about the usage and adoption of ophthalmic drugs in various indications and regions. Additionally, key stakeholders can find out the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years, along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Furthermore, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the Ophthalmic Drugs market.
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Drivers for Pharmaceutical Demand
1.1.2 Region-wise Pharmaceutical Spending
1.1.3 R&D Pipeline in the Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.2.1 Trends in the Ophthalmic Drugs Market
3.3 Related Markets
3.3.1 Bacterial Conjunctivitis Drugs
3.3.2 Contact Lenses
3.3.2.1 Trends in the contact lens market
4 Market Outline
4.1 Ophthalmic Drugs Approved by FDA
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of eye diseases
5.1.1.2 Increasing prevalence of cataract
5.1.1.3 Increasing aging population
5.1.2 Opportunities
5.1.2.1 Increasing mergers & acquisitions
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Loss of patent for blockbuster drugs
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Indication: Market Size and Analysis
6.1 Overview
6.2 Dry Eyes
6.3 Glaucoma
6.4 Eye Infection/Inflammation
6.5 Retinal Disorder
6.6 Others
7 Regions: Market Size and Analysis
7.1 Overview
7.2 North America
7.2.1 Overview
7.3 Europe
7.3.1 Overview
7.4 Asia Pacific
7.4.1 Overview
7.5 Rest of the World
7.5.1 Overview
8 Competitive Landscape
9 Vendors Profile
9.1 Allergan PLC
9.1.1 Overview
9.1.2 Business Units
9.1.3 Geographic Revenue
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategies
9.2 Novartis AG
9.2.1 Overview
9.2.2 Business Units
9.2.3 Geographic Revenue
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategies
9.3 Pfizer Inc.
9.3.1 Overview
9.3.2 Business Units
9.3.3 Geographic Revenue
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategies
9.4 Valeant Pharmaceuticals International Inc. (Bausch Health)
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Revenue
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Santen Pharmaceutical Co., Ltd.
9.5.1 Overview
9.5.2 Business Units
9.5.3 Geographic Revenue
9.5.4 Business Focus
9.5.5 SWOT Analysis
9.5.6 Business Strategies
9.6 Akorn Inc.
9.6.1 Overview
9.6.2 Business Focus
9.6.3 SWOT Analysis
9.6.4 Business Strategies
9.7 Johnson & Johnson
9.7.1 Overview
9.7.2 Business Units
9.7.3 Geographic Revenue
9.7.4 Business Focus
9.7.5 SWOT Analysis
9.7.6 Business Strategies
10 Companies to Watch for
10.1 Shire plc
10.1.1 Overview
10.1.2 Highlights
10.2 Daiichi Sankyo, Inc.
10.2.1 Overview
10.2.2 Highlights
10.3 Bayer AG
10.3.1 Overview
10.4 F. Hoffmann-La Roche (Genentech)
10.4.1 Overview
10.5 Sun Pharmaceuticals
10.5.1 Overview
10.5.2 Highlights
Annexure
Abbreviations
TABLE 1 NOVARTIS AG: OFFERINGS 60
TABLE 2 NOVARTIS AG: RECENT DEVELOPMENTS 62
TABLE 3 PFIZER INC.: OFFERINGS 68
TABLE 4 PFIZER INC.: RECENT DEVELOPMENTS 68
TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 72
TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 73
TABLE 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS 78
TABLE 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 79
TABLE 9 AKORN INC: OFFERINGS 83
TABLE 10 AKORN INC.: RECENT DEVELOPMENTS 84
TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 88
TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 88
TABLE 13 SHIRE PLC: OVERVIEW 96
TABLE 14 SHIRE PLC: RECENT DEVELOPMENTS 96
TABLE 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 98
TABLE 16 BAYER AG: OVERVIEW 99
TABLE 17 BAYER AG: RECENT DEVELOPMENTS 99
TABLE 18 F. HOFFMANN-LA ROCHE: OVERVIEW 100
TABLE 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 100
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
